University of Arizona Cancer Center - Academic Profile

Publications

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Jeffrey S. Weber , Steven O’Day , Walter J. Urba +5 more

Purpose The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Seconda...

2008 Journal of Clinical Oncology 458 citations

Affiliated Researchers

Institution Info

Type: healthcare
Country: N/A
Publications: 2
Citations: 1,986

External Links

Identifiers

ROR: https://ror.org/04tvx8690

Publications

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Affiliated Researchers

Lee D. Cranmer

Geoff Nichol

Michael Yellin

Jolie Snively

Evan M. Hersh

Institution Info

External Links

Identifiers